NCT05765266View on ClinicalTrials.gov

ACP Max™ PRP System for Knee Osteoarthritis: A Feasibility Trial

NAActive, not recruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

May 13, 2024

Primary Completion Date

July 15, 2025

Study Completion Date

July 15, 2026

Conditions
Knee Osteoarthritis
Interventions
DEVICE

ACP Max™

Single 4-6 ml intra-articular (IA) injection of the output of ACP Max™

DEVICE

Depo-Medrol®

Single IA injection of 40 mg of methylprednisolone acetate (1 ml of solution) mixed with 5 ml of Normal Saline for a total of 6 ml.

Trial Locations (3)

24541

Spectrum Medical, Inc., Danville

27103

The Center for Clinical Research, Winston-Salem

37920

AMR Knoxville, Knoxville

Sponsors

Lead Sponsor

Arthrex, Inc.
All Listed Sponsors
lead

Arthrex, Inc.

INDUSTRY

NCT05765266 - ACP Max™ PRP System for Knee Osteoarthritis: A Feasibility Trial | Biotech Hunter | Biotech Hunter